Publicador de contenidos

Back to La revista Time informa de investigaciones sobre cáncer en la Universidad de Navarra y dos centros de EE. UU.

Time' magazine reports on cancer research at the University of Navarra and two U.S. centers.

The report refers to the personalized vaccine against follicular lymphoma from Dr. Maurizio Bendandi's team.

Image description
PHOTO: Manuel Castells
23/04/07 12:06 Mª Pilar Huarte

In this week's issue , dated April 23, Time magazine reports on a personalized vaccine treatment for follicular lymphoma patients. With this new therapy, the immune system itself, stimulated by the vaccine, is able to kill tumor cells that had resisted chemotherapy.

The protagonist of the report graduate "The disease is the remedy" is Dr. Maurizio Bendandi. This specialist works in two entities of the University of Navarra that collaborate very closely: the research center Médica Aplicada (CIMA) and the Clínica Universitaria de Navarra.

Time recalls that the research of Dr. Bendandi and his team was published in September 2006 in the scientific journal Journal of the National Cancer Institute of the USA. The other two centers mentioned by Time as being the only ones researching and treating patients with this non-conventional therapy are North American: the MD Anderson Cancer Center, in Houston (Texas) and Stanford University (California).

In fact, before joining the University of Navarra, Maurizio Bendandi developed his research at the U.S. National Cancer high school , where he worked with Larry Kwak, today director associate at MD Anderson.

article in the journal

BUSCADOR NOTICIAS

SEARCH ENGINE NEWS

From

To